Cerebrolysin in SAH (Subarachnoidal Haemorrhage) - Observational Study

Completed

• Conditions: SAH (Subarachnoid Hemorrhage)

• Registration Number: NCT06429943
• Lead Sponsor: Pomeranian Medical University Szczecin

Brief Summary

Subarachnoid haemorrhage often affects people in middle age and is associated with high mortality or neurological damage. In recent years, advances in surgical techniques have im-proved the mortality rate. However, there is still need for the research for the optimal possible final effect of treatment. In our study, we've decided to examine the effect of a multimodal approach including Cerebrolysin in the supportive treatment of patients. We've examined the supply of neuroprotective drugs and neuromonitoring.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-15
• Primary Completion: 2022-10-15
• Study Completion: 2023-01-10
• Status Verified: 2023-12
• Study First Submitted: 2024-05-21
• Study First Submitted QC: 2024-05-21
• Last Update Submitted: 2024-05-21
• Study First Posted: 2024-05-28
• Last Update Posted: 2024-05-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

• age >18 years old, diagnosis of SAH, treatment in ICU conditions

Exclusion Criteria

• age <18 years, medical history of allergy to Cerebrolysin, acute renal failure, pregnancy, multi organ trauma, death within 48 hours after admission

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
GOS Glasgow Outcome Scale	1 month	Glasgow Outcome Scale - 5 points scale, characterizing the patients' deficits

Secondary Outcome Measures

Name	Time	Method
LOS Length of Stay	hospitalisation time	length of stay in days, that patient spent in hospital/ intensive care unit
mortality	1 month	mortality

Trial Locations

Locations (1)

Pomeranian Medical University, University Hospital no.1; 🇵🇱 Szczecin, Poland